Key Takeaways & Executive Findings
- •• Preoperative anemia is an independent risk factor for lower extremity deep vein thrombosis (DVT) after elective lumbar fusion, with an odds ratio of 4.221. • The incidence of preoperative anemia was significantly higher in patients who developed DVT (32.6%) compared to those who did not (10.9%). • D-dimer positivity was also identified as a significant risk factor for DVT, with an odds ratio of 2.023. • The study recommends active management and correction of preoperative anemia to reduce the risk of DVT in patients undergoing elective lumbar fusion.
Abstract
BACKGROUND: Lower extremity deep vein thrombosis is a catastrophic complication after lumbar spine fusion, and previous studies have shown that some patients, such as those with prosthetic arthroplasty and abdominal surgeries, suffer from a combination of preoperative anemia, which predisposes them to postoperative deep vein thrombosis of the lower extremities. However, whether preoperative anemia increases the risk of lower extremity deep vein thrombosis after lumbar spine fusion is unclear. OBJECTIVE: To investigate the correlation between preoperative anemia and deep vein thrombosis of the lower extremities in patients after lumbar fusion. METHODS: The clinical data of 1 178 patients who underwent lumbar spinal fusion treatment admitted to Third Affiliated Hospital of Anhui Medical University from January 2020 to December 2023 were retrospectively analyzed. According to whether or not the patients developed lower extremity deep vein thrombosis after the operation, the patients were divided into the deep vein thrombosis group (ultrasound report suggestive of lower extremity deep vein thrombosis) and the non-deep vein thrombosis group (ultrasound report suggestive of no lower extremity deep vein thrombosis). The incidence of anemia was compared between the two groups, and risk factors for lower extremity deep vein thrombosis in lumbar fusion patients were determined by univariate analysis and multivariate logistic regression analysis. RESULTS AND CONCLUSION: Among 1 178 patients, there were 43 cases (3.7%) in the deep vein thrombosis group and 1 135 cases (96.4%) in the non-deep vein thrombosis group. The incidence of preoperative anemia in the deep vein thrombosis group was 32.6%, significantly higher than that in the non-deep vein thrombosis group (10.9%, P < 0.05). Univariate analysis showed significant differences between the two groups in preoperative hemoglobin (P < 0.001), preoperative red blood cell count (P=0.028), D-dimer positivity (P=0.029), hypertension (P=0.019), number of fused segments (P=0.023), anemia (P < 0.001), and blood transfusion (P=0.006) (P < 0.05). Multivariate analysis showed that preoperative anemia (OR=4.221, 95%CI: 1.198-14.802, P=0.025) and D-dimer positivity (OR=2.023, 95%CI: 1.065-3.844, P=0.031) were risk factors for lower extremity deep vein thrombosis after lumbar fusion. These findings suggest that the incidence of preoperative anemia is relatively high in patients undergoing elective lumbar fusion, and preoperative anemia is an independent risk factor for deep vein thrombosis after lumbar fusion. It is recommended that preoperative anemia should be actively managed and corrected before elective lumbar fusion to reduce the risk of lower extremity deep vein thrombosis.
1. Introduction
Lumbar fusion is one of the common surgical procedures for adults with degenerative disc disease and lumbar spondylolisthesis causing chronic and debilitating symptoms [1-3]. Lower extremity deep vein thrombosis (DVT) is a common complication after elective orthopedic surgery and is an important factor leading to increased morbidity and mortality. According to studies by ZHAO et al. [4] and STROM et al. [5], the incidence of lower extremity DVT reaches 11.8% and 15.3%, respectively. Notably, DVT often lacks obvious symptoms, and routine lower extremity ultrasound screening has low sensitivity for asymptomatic DVT. In many cases, fatal pulmonary embolism is the first manifestation of lower extremity DVT. Therefore, identifying risk factors for DVT after lumbar fusion is particularly important.
For patients undergoing lumbar fusion, hemoglobin levels are often decreased due to advanced age, poor nutritional status, and unknown reasons. According to the National Health and Nutrition Examination Survey (NHANES), anemia is more common in the elderly than in younger individuals [6]. Studies have found considerable evidence of a significant association between preoperative anemia and surgical complications and mortality [7-10]. BARON et al. [11] studied 227,435 patients undergoing non-cardiac surgery and found that patients with preoperative hemoglobin below normal had higher in-hospital mortality than those with normal levels. Although preoperative anemia is not a direct causative factor for DVT, it significantly increases the risk of postoperative DVT through various indirect pathways, including tissue hypoxia/endothelial injury, hemodynamic changes, pro-inflammatory state, increased transfusion requirements, and limited mobility. Anemia often signals poor overall health and the presence of other potential prothrombotic factors [12-13]. However, in some domestic and international studies, it remains unclear whether preoperative anemia increases the incidence of lower extremity DVT after lumbar fusion.
Given this, the purposes of this study were: (1) to investigate the prevalence of preoperative anemia in patients undergoing lumbar fusion; (2) to investigate the incidence of lower extremity DVT; and (3) to determine whether preoperative anemia is a risk factor for lower extremity DVT after lumbar fusion.
Loading authentic research manuscript (Pages 1–5)...
ZHANG Haoliang, WANG Zhibing, SHAN Tao, HAN Guosong, LI Chun (2026). Correlation between preoperative anemia and lower extremity deep vein thrombosis in patients after elective lumbar fusion. Chinese Journal of Tissue Engineering Research. https://doi.org/10.12307/2026.21624
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the main finding of this study?
The study found that preoperative anemia is an independent risk factor for lower extremity deep vein thrombosis (DVT) after elective lumbar fusion, with an odds ratio of 4.221 (95% CI: 1.198-14.802).
How many patients were included in the study?
The study included 1,178 patients who underwent lumbar spinal fusion at the Third Affiliated Hospital of Anhui Medical University from January 2020 to December 2023.
What was the incidence of deep vein thrombosis in the study cohort?
The incidence of deep vein thrombosis was 3.7% (43 out of 1,178 patients).
What other risk factors were identified for deep vein thrombosis?
In addition to preoperative anemia, D-dimer positivity was also identified as a significant risk factor, with an odds ratio of 2.023 (95% CI: 1.065-3.844).
What is the clinical implication of this study?
The study suggests that clinicians should actively manage and correct preoperative anemia before elective lumbar fusion to reduce the risk of lower extremity deep vein thrombosis.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.